Key facts
- This page summarizes Richard Kuntz's Form 4 filing for DiaMedica Therapeutics Inc. (DMAC).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 03 Jun 2025, 16:16.
Richard Kuntz - 01 Jun 2025 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)
- Reporting relationship
- Director
- Issuer ticker
- DMAC
- Reported as of
- 01 Jun 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jun 2025, 16:16:41 UTC
- Prior SEC filing
- 09 May 2025
- Next SEC filing
- 02 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Scott Kellen, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Richard Kuntz filed Form 4 for DiaMedica Therapeutics Inc. (DMAC) on 03 Jun 2025.
Change
- Previous filing in this sequence was filed on 09 May 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001341125
Primary reporting owner
Kuntz Richard
- Relationship
- Director
- Address
- 301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS
- Signature
- /s/ Scott Kellen, attorney-in-fact
- Signature date
- 03 Jun 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DMAC
holding
Voting Common Shares, no par value per share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 24,210
- Date
- 01 Jun 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DMAC
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +32,162
- Change %
- Price
- $0.000000
- Shares after
- 32,162
- Date
- 01 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 32,162
- Exercise price
- $4.11
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Includes 7,443 shares issuable on vesting of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan.
Footnote F2
Vests in four nearly equal quarterly installments over one year.